Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia

Schizophrenia Research

Volumn 119, Issue 1-3, 2010, Pages 47-51

  Jindal, Ripu D ^a,b   Pillai, Anil K ^c   Mahadik, Sahebrao P ^c   Eklund, Kevin ^a   Montrose, Debra M ^a   Keshavan, Matcheri S ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BDNF; Neuroplasticity; Psychosis; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; HUMAN; MALE; NERVE CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SCHIZOPHRENIA; SEX DIFFERENCE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REFERENCE VALUES; SCHIZOPHRENIA; SEX FACTORS; YOUNG ADULT;

EID: 77952670145     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.12.035     Document Type: Article

References (54)

1. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389:856-860.
2. Diagnostic and statistical manual of mental disorders (4th ed.) 1994, American Psychiatric Association, American Psychiatric Press, Washington, DC. 4th ed.
3. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) 1983, University of Iowa, Iowa City: IA.
4. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa, Iowa City: IA.
5. Angelucci F., Aloe L., Iannitelli A., Gruber S.H., Mathe A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur. Neuropsychopharmacol. 2005, 15:311-317.
6. Angelucci F., Mathe A.A., Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J. Neurosci. Res. 2000, 60:783-794.
7. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 2003, 71:127-131.
8. Bramham C.R., Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog. Neurobiol. 2005, 76:99-125.
9. Buckley P.F., Mahadik S., Pillai A., Terry A. Neurotrophins and schizophrenia. Schizophr. Res. 2007, 94:1-11.
10. Buckley P.F., Pillai A., Evans D., Stirewalt E., Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr. Res. 2007, 91:1-5.
11. Bueller J.A., Aftab M., Sen S., Gomez-Hassan D., Burmeister M., Zubieta J.K. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol. Psychiatry 2006, 59:812-815.
12. Carvalho A.L., Caldeira M.V., Santos S.D., Duarte C.B. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br. J. Pharmacol. 2008, 153(Suppl 1):S310-S324.
13. Chen, D.C., Wang, J., Wang, B., Yang, S.C., Zhang, C.X., Zheng, Y.L., Li, Y.L., Wang, N., Yang, K.B., Xiu, M.H., Kosten, T.R., Zhang, X.Y., 2009. Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) (2009 Sep 29).
14. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 2001, 52:79-86.
15. Egan M.F., Weinberger D.R. Neurobiology of schizophrenia. Curr. Opin. Neurobiol. 1997, 7:701-707.
16. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 2000, 14:1-21.
17. First M.D., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV Axis I disorders - patient edition 1995, Biometrics Research Department, NYSPI, New York.
18. Fisher M., Holland C., Merzenich M.M., Vinogradov S. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am. J. Psychiatry 2009, 166:805-811.
19. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 2000, 57:65-73.
20. Grassi-Oliveira R., Stein L.M., Lopes R.P., Teixeira A.L., Bauer M.E. Low plasma brain-derived neurotrophic factor and childhood physical neglect are associated with verbal memory impairment in major depression-a preliminary report. Biol. Psychiatry 2008, 64:281-285.
21. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J. Psychiatr. Res. 2007, 41:31-35.
22. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001, 411:86-89.
23. Guzman-Marin R., Ying Z., Suntsova N., Methippara M., Bashir T., Szymusiak R., et al. Suppression of hippocampal plasticity-related gene expression by sleep deprivation in rats. J. Physiol. 2006, 575:807-819.
24. Hall H., Lawyer G., Sillen A., Jonsson E.G., Agartz I., Terenius L., Arnborg S. Potential genetic variants in schizophrenia: a Bayesian analysis. World J. Biol. Psychiatry 2007, 8:12-22.
25. Hariri A.R., Goldberg T.E., Mattay V.S., Kolachana B.S., Callicott J.H., Egan M.F., Weinberger D.R. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J. Neurosci. 2003, 23:6690-6694.
26. Hill J.J., Kolluri N., Hashimoto T., Wu Q., Sampson A.R., Monteggia L.M., Lewis D.A. Analysis of pyramidal neuron morphology in an inducible knockout of brain-derived neurotrophic factor. Biol. Psychiatry 2005, 57:932-934.
27. Kapczinski F., Frey B.N., Kauer-Sant'Anna M., Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev. Neurother. 2008, 8:1101-1113.
28. Karege F., Schwald M., Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci. Lett. 2002, 328:261-264.
29. Keshavan M.S. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J. Psychiatr. Res. 1999, 33:513-521.
30. Krystal J.H., Tolin D.F., Sanacora G., Castner S.A., Williams G.V., Aikins D.E., et al. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discov. Today 2009, 14:690-697.
31. Lang U.E., Hellweg R., Seifert F., Schubert F., Gallinat J. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol. Psychiatry 2007, 62:530-535.
32. Lewin G.R., Barde Y.A. Physiology of the neurotrophins. Annu. Rev. Neurosci. 1996, 19:289-317.
33. Maisonpierre P.C., Le Beau M.M., Espinosa R., Ip N.Y., Belluscio L., de la Monte S.M., et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 1991, 10:558-568.
34. Mattson M.P. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann. N. Y. Acad. Sci. 2008, 1144:97-112.
35. Mu J.S., Li W.P., Yao Z.B., Zhou X.F. Deprivation of endogenous brain-derived neurotrophic factor results in impairment of spatial learning and memory in adult rats. Brain Res. 1999, 835:259-265.
36. Murer M.G., Yan Q., Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 2001, 63:71-124.
37. Ozan E., Okur H., Eker C., Eker O.D., Gönül A.S., Akarsu N. The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels. Brain Res. Bull. 2010, 81(1):61-65.
38. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37:1553-1561.
39. Parikh V., Evans D.R., Khan M.M., Mahadik S.P. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr. Res. 2003, 60:117-123.
40. Patterson S.L., Abel T., Deuel T.A., Martin K.C., Rose J.C., Kandel E.R. Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron 1996, 16:1137-1145.
41. Piccinni A., Marazziti D., Del Debbio A., Bianchi C., Roncaglia I., Mannari C., et al. Diurnal variation of plasma brain-derived neurotrophic factor (BDNF) in humans: an analysis of sex differences. Chronobiol. Int. 2008, 25:819-826.
42. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2:24-32.
43. Rizos E.N., Rontos I., Laskos E., Arsenis G., Michalopoulou P.G., Vasilopoulos D., et al. Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1308-1311.
44. Sartorius A., Hellweg R., Litzke J., Vogt M., Dormann C., Vollmayr B., et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009, 42:270-276.
45. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry 1999, 45(1):17-25.
46. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 2008, 64:527-532.
47. Shoval G., Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur. Neuropsychopharmacol. 2005, 15:319-329.
48. Shugart Y.Y., Chen L., Day I.N., Lewis S.J., Timpson N.J., Yuan W., et al. Two British women studies replicated the association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI. Eur. J. Hum. Genet. 2009, 17:1050-1055.
49. Stern A.J., Savostyanova A.A., Goldman A., Barnett A.S., van der Veen J.W., Callicott J.H., et al. Impact of the brain-derived neurotrophic factor Val66Met polymorphism on levels of hippocampal N-acetyl-aspartate assessed by magnetic resonance spectroscopic imaging at 3 Tesla. Biol. Psychiatry 2008, 64:856-862.
50. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995, 270:593-598.
51. Vinogradov S., Fisher M., Holland C., Shelly W., Wolkowitz O., Mellon S.H. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?. Biol. Psychiatry 2009, 66:549-553.
52. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2003, 8:592-610.
53. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., Hyde T.M., Herman M.M., et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2005, 10:637-650.
54. Wong J., Webster M.J., Cassano H., Weickert C.S. Changes in alternative brain-derived neurotrophic factor transcript expression in the developing human prefrontal cortex. Eur. J. NeuroSci. 2009, 29:1311-1322.